» Articles » PMID: 3142085

Diurnal Variation of the Fibrinolytic System

Overview
Journal Thromb Haemost
Publisher Thieme
Date 1988 Jun 16
PMID 3142085
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

To elucidate which component(s) of the fibrinolytic system is (are) responsible for the diurnal variation of fibrinolytic activity we have studied several parameters of this system in 8 healthy male volunteers during a period of 24 h. Blood was collected at 8 a.m., 10 a.m., 12 a.m., 4 p.m., 8 p.m. and 8 a.m. next morning. The following tests were performed: euglobulin clot lysis time (ECLT), fibrinolytic activity of euglobulins on fibrin plates in the presence and absence of blocking antibodies to tissue-type plasminogen activator (t-PA) and/or urokinase (u-PA), overall plasminogen activator inhibitor (PAI) activity, antigen levels of t-PA, u-PA and PAI-1 and zymography of the euglobulin fraction after SDS-PAGE. From 8-10 a.m. to 4-8 p.m., total fibrinolytic activity increased by 113% (p less than 0.01) or 71% (p less than 0.01) when measured by ECLT or by fibrin plate assay, respectively. The immunoquenching experiments showed that this increase was entirely due to t-PA related activity whereas u-PA activity and t-PA/u-PA independent activity remained constant during the day. Average antigen levels of u-PA and t-PA in the afternoon were 6% and 25% lower than those measured in the morning. During this period, overall PAI activity and PAI-1 antigen decreased by 31% (p less than 0.01) and 52% (p less than 0.01) respectively. Electrophoretic-zymographic analysis of the euglobulins revealed that throughout the day the majority of t-PA was present in the form of the 110 kDa t-PA/PAI-1 complex. The intensity of this complex was lowest in the afternoon.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis.

Zheng Z, Mukhametova L, Boffa M, Moore E, Wolberg A, Urano T J Thromb Haemost. 2023; 21(4):1043-1054.

PMID: 36759279 PMC: 10109242. DOI: 10.1016/j.jtha.2023.01.008.


Euglobulin clot lysis time reveals a high frequency of fibrinolytic activation in trauma.

Ilich A, Kumar V, Ferrara M, Henderson M, Noubouossie D, Jenkins D Thromb Res. 2021; 204:22-28.

PMID: 34111811 PMC: 8277746. DOI: 10.1016/j.thromres.2021.05.017.


Altered Daytime Fluctuation Pattern of Plasminogen Activator Inhibitor 1 in Type 2 Diabetes Patients with Coronary Artery Disease: A Strong Association with Persistently Elevated Plasma Insulin, Increased Insulin Resistance, and Abdominal Obesity.

Lalic K, Jotic A, Rajkovic N, Singh S, Stosic L, Popovic L Int J Endocrinol. 2015; 2015:390185.

PMID: 26089884 PMC: 4451778. DOI: 10.1155/2015/390185.


Circadian variation in the effect of intravenous thrombolysis after non-lacunar stroke.

Cappellari M, Bovi P, Moretto G J Thromb Thrombolysis. 2014; 38(2):253-9.

PMID: 24402193 DOI: 10.1007/s11239-013-1041-6.


Individual lytic efficacy of recombinant tissue plasminogen activator in an in vitro human clot model: rate of "nonresponse".

Meunier J, Wenker E, Lindsell C, Shaw G Acad Emerg Med. 2013; 20(5):449-55.

PMID: 23672358 PMC: 3658149. DOI: 10.1111/acem.12133.